Sahira Chaiben,Peggy Gandia,Béatrice Duly-Bouhanick et al.
Sahira Chaiben et al.
Background and objective: Accurate assessment of drug adherence is essential for long-term oral therapies, where self-administration is unsupervised. Conventional tools such as self-reports, electronic monitors, and even ...
Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma [0.03%]
依拉纳单抗药代动力学及细胞因子释放综合征暴露反应关系在复发/难治多发性骨髓瘤患者中的研究
Jennifer E Hibma,Donald Irby,Alan Liu et al.
Jennifer E Hibma et al.
Background and objective: A population pharmacokinetics (PopPK) model was developed for elranatamab, a bispecific antibody targeting both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), to charact...
Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation [0.03%]
口服TKI和PARP抑制剂的治疗药物监测及基于模型的精准给药实践框架
Arnau Torrent-Rodríguez,Carla Bastida,Esther Carcelero San Martín et al.
Arnau Torrent-Rodríguez et al.
Oral tyrosine kinase inhibitors and poly (adenosine diphosphate-ribose) polymerase inhibitors are widely used across solid tumors and hematologic malignancies and are typically administered at fixed doses. However, substantial interindividu...
A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study [0.03%]
基于真实世界数据的模型驱动预测甲氨蝶呤所致儿童骨肉瘤患者急性肾损伤的多中心药代动力学研究模型驱动型早期预测模型在儿童骨肉瘤患者中应用的真实世界数据分析：一项多中心药代动力学研究
Patricia Rega,Jorge Morales Vallespin,Azucena Aldaz et al.
Patricia Rega et al.
Background and objective: High-dose methotrexate is central to pediatric osteosarcoma treatment, but delayed elimination increases the risk of acute kidney injury, compromising treatment intensity. Current therapeutic dru...
Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization [0.03%]
药物相互作用研究中代谢物药代动力学数据采集的工业实践及应用回顾分析
Tatyana Dubich,Thijs van Iersel,Kamelia Mirdamadi et al.
Tatyana Dubich et al.
Introduction: Systemic exposure of a sensitive probe is considered a 'gold standard' for assessment of clinical relevance of a potential cytochrome P450 (CYP)-driven drug-drug interaction (DDI). Typically, the change in s...
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide [0.03%]
肾或肝功能损害不影响皮下注射Cagrilintide的药代动力学、安全性和耐受性
Mette J F Nielsen,Niels-Peter Becker,Helene H Hansen Duus et al.
Mette J F Nielsen et al.
Background and objectives: Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide ...
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis [0.03%]
血管性转甲状腺素蛋白淀粉样变患者中新型寡核苷酸药物vutrisiran介导的转甲状腺素蛋白下降作用研究
Marianna Fontana,Vincent Algalarrondo,Pablo Garcia-Pavia et al.
Marianna Fontana et al.
Background and objective: We assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across subpopulations of patients with hereditary TTR amyloidosis (ATTR) with p...
Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review [0.03%]
免疫球蛋白的群体药代动力学和药效学：系统性综述
S L van der Zeeuw,S J van Tilburg,B C Jacobs et al.
S L van der Zeeuw et al.
Background and objective: Intravenous and/or subcutaneous immunoglobulins (IVIg/SCIg) are used as immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiencies (PID/SID) and as immunomodulatory the...
Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection [0.03%]
用于治疗基因1-6型慢性丙型肝炎病毒感染的三岁（含）至小于十八岁（含）儿科患者 glecaprevir 和 pibrentasvir 药代动力学分析
Neha Thakre,Denise Beck,Ahmed M Saeed et al.
Neha Thakre et al.
Background: Mavyret, a combination medication of glecaprevir (GLE) and pibrentasvir (PIB), is approved to treat chronic and acute hepatitis C virus (HCV) (genotypes 1-6) infection in adults and pediatric patients ≥ 3 yea...
Impact of Preclinical Verification in Physiologically Based Pharmacokinetic Modelling for First-in-Human Predictions: Application of a Published Model Building Strategy for Five Compounds [0.03%]
基于生理的药代动力学模型中预验证对首次人体预测的影响：五种化合物应用已发表的建模策略的例子
Claire Jackson,Rebecca H Graves,Thuy T Tran et al.
Claire Jackson et al.
Background and objective: Physiologically based pharmacokinetic modelling is routinely used in the pharmaceutical industry and has an impact on drug labels. New applications have emerged, one of which is first-in-human ph...